JenniferAnnWoyachMD

PubMed

• Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma accounting for small molecule inhibitors: A real-world cohort analysis.
  Adam S Kittai, Ying Hang, Seema A Bhat, Abi Clark, Michael Grever, Joanna M Rhodes, Melyssa Roberts, Kerry A Rogers, Anna Teschemaker, Maria Munoz-Sagastibelza, Jennif...> ;American Journal of Hematology. 2024 Apr 1
• Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.
  Adam S Kittai, David Bond, Ying Huang, Seema A Bhat, Emily Blyth, John C Byrd, Julio C Chavez, Matthew S Davids, Jamie P Dela Cruz, Mark R Dowling, Caitlyn Duffy, Carr...> ;Journal of Clinical Oncology. 2024 Mar 29
• A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
  Paul Joseph Hampel, Kerry A Rogers, Wei Ding, Saad S Kenderian, Sameer A Parikh, Mahesh Swaminathan, Erin M Parry, Jan A Burger, Matthew S Davids, Alessandra Ferrajoli...> ;Blood Advances. 2024 Mar 27
• Long-read single-cell RNA sequencing enables the study of cancer subclone-specific genotype and phenotype in chronic lymphocytic leukemia.
  Gage S Black, Xiaomeng Huang, Yi Qiao, Philip Moos, Deepa Sampath, Deborah M Stephens, Gabor T Marth, Jennifer A Woyach> ;Biorxiv. 2024 Mar 16
• The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signa...
  Alexander R Marr, Madeline Halpin, Dominique L Corbin, Yerdanos Asemelash, Steven Sher, Britten K Gordon, Ethan C Whipp, Shaneice Mitchell, Bonnie K Harrington, Shelle...> ;Experimental Hematology & Oncology. 2024 Mar 4
• Comparison of karyotype scoring guidelines for evaluating karyotype complexity in chronic lymphocytic leukemia.
  Avenarius, M., Huang, Y., Miller, C., Kittai, A., Bhat, S., Rogers, K., Grever, M., Woyach, J.> ;Leukemia. 2024 Mar 1
• Long-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL.
  Barr, P. M., Barr, P. M., Barr, P. M., Jennifer A Woyach, Gabriela E Perez Burbano, Amy S Ruppert, Cecelia R Miller, Nyla A Heerema, Weiqiang Zhao, Anna Wall, Wei Ding...> ;Blood. 2024 Jan 12
• A Bayesian framework to study tumor subclone-specific expression by combining bulk DNA and single-cell RNA sequencing data.
  Qiao, Y., Huang, X., Moos, P., Ahmann, J., Pomicter, A., Marth, G., Deininger, M., Byrd, J., Woyach, J., Stephens, D.> ;Genome Research. 2024 Feb 7
• Active Hexose-Correlated Compound Shows Direct and Indirect Effects against Chronic Lymphocytic Leukemia.
  Merchand-Reyes, G., Santhanam, R., Valencia-Pena, M., Kumar, K., Mo, X., Belay, T., Mundy-Bosse, B., Tridandapani, S., Butchar, J., Woyach, J.> ;Nutrients. 2023 Dec 18
• Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled An...
  Sathej Gopalakrishnan, Rajeev Menon, Ahmed A Suleiman, Arnon P Kater, Stephan Stilgenbauer, John F Seymour, Brenda Chyla, Tong Lu, Su Young Kim, Andrew W Roberts, Jenn...> ;Hemasphere. 2023 Dec 1
• 2 citations
  First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma.
  Jennifer A Woyach, Ian W Flinn, Seema A Bhat, Ronald E Savage, Feng Chai, Sudharshan Eathiraj, Sean D Reiff, Elizabeth M Muhowski, Lindsey Granlund, Lyndsey Szuszkiewi...> ;Cancer Discovery. 2024 Jan 12
• Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization.
  Samantha M Teierle, Ying Huang, Adam S Kittai, Seema A Bhat, Michael Grever, Kerry A Rogers, Weiqiang Zhao, Daniel Jones, John C Byrd, Matthew R Avenarius, Nyla A Heer...> ;Blood Advances. 2023 Dec 12
• 3 citations
  Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia:State-of-the-Art Review.
  Kola-Kehinde, O., Cooper Quartermaine, Sanam M Ghazi, Aneeq Yasin, Farrukh T Awan, Michael Fradley, Tracy Wiczer, Sujay Kalathoor, Mussammat Ferdousi, Satyam Krishan, ...> ;JACC. Cardiooncology. 2023 Oct 1
• 21 citations
  Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
  Anthony R Mato, Jennifer A Woyach, Jennifer R Brown, Paolo Ghia, Krish Patel, Toby A Eyre, Talha Munir, Ewa Lech-Maranda, Nicole Lamanna, Constantine S Tam, Nirav N Sh...> ;The New England Journal of Medicine. 2023 Jul 6
• 4 citations
  Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia.
  Johnson, P., Woyach, J., Ulrich, A., Marcotte, V., Nipp, R., Lage, D., Nelson, A., Newcomb, R., Rice, J., Lavoie, M., Ritchie, C., Bartlett, N., Stephens, D., Ding, W....> ;Journal of Geriatric Oncology. 2023 Jul 1
• 14 citations
  Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.
  John F Seymour, John C Byrd, Paolo Ghia, Arnon P Kater, Asher Chanan-Khan, Richard R Furman, Susan O'Brien, Jennifer R Brown, Talha Munir, Anthony Mato, Stephan Stilge...> ;Blood. 2023 Aug 24
• 2 citations
  B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy.
  Jennifer A Woyach, Paolo Ghia, John C Byrd, Inhye E Ahn, Carol Moreno, Susan M O'Brien, Daniel Jones, Leo W K Cheung, Elizabeth Chong, Kevin Kwei, James P Dean, Danell...> ;Clinical Cancer Research. 2023 Aug 15
• Correction: Evaluation of bleeding events in patients receiving acalabrutinib therapy.
  Pooja S Kumar, Tracy Wiczer, Lindsay Rosen, Arthur J Pollauf, Amy Zheng, Marilly Palettas, Leylah Azali, Seema A Bhat, John C Byrd, Michael R Grever, Kerry A Rogers, J...> ;Leukemia. 2023 Jul 1
• Refining prognosis in chronic lymphocytic leukemia with normal Fluorescence in situ hybridization results.
  Matthew R Avenarius, Ying Huang, Jonathan Hyak, John C Byrd, Seema A Bhat, Michael Grever, Adam S Kittai, Kerry A Rogers, Dan Jones, Weiqiang Zhao, Nyla A Heerema, Lyn...> ;Hematological Oncology. 2023 Oct 1
• Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell-targeted therapy.
  Joseph H Azar, John P Evans, Madison H Sikorski, Karthik B Chakravarthy, Selah McKenney, Ian Carmody, Cong Zeng, Rachael Teodorescu, No-Joon Song, Jamie L Hamon, Donna...> ;JCI Insight. 2023 Mar 22
• 1 citations
  Evaluation of bleeding events in patients receiving acalabrutinib therapy.
  Pooja S Kumar, Tracy Wiczer, Lindsay Rosen, Arthur J Pollauf, Amy Zheng, Marilly Palettas, Leylah Azali, Seema A Bhat, John C Byrd, Michael R Grever, Kerry A Rogers, J...> ;Leukemia. 2023 Jul 1
• 4 citations
  Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated Cardiotoxicity.
  Benjamin Buck, Aaron P Chum, Mitkumar Patel, Rebecca Carter, Haseeb Nawaz, Vedat Yildiz, Patrick Ruz, Tracy Wiczer, Kerry A Rogers, Farrukh T Awan, Seema Bhat, Avirup ...> ;JAMA Oncology. 2023 Apr 1
• 9 citations
  VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia.
  Sher, S., Whipp, E., Walker, J., Zhang, P., Beaver, L., Williams, K., Orwick, S., Ravikrishnan, J., Walker, B., Perry, E., Gregory, C., Purcell, M., Pan, A., Yan, P., ...> ;Leukemia. 2023 Feb 1
• 1 citations
  Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study.
  Jennifer A Woyach, Paul M Barr, Thomas J Kipps, Jacqueline C Barrientos, Inhye E Ahn, Paolo Ghia, Vincent Girardi, Emily Hsu, Mandy Jermain, Jan A Burger> ;Cancers. 2023 Jan 13
• 9 citations
  Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter's transformation.
  Zachary A Hing, Janek S Walker, Ethan C Whipp, Lindsey Brinton, Matthew Cannon, Pu Zhang, Steven Sher, Casey B Cempre, Fiona Brown, Porsha L Smith, Claudio Agostinelli...> ;Nature Communications. 2023 Jan 6
• Join now to see all

Journal Articles

• Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia  
  Jennifer Woyach, MD, Cancer Discovery
• Ibrutinib and Aspergillus: A Btk-Targeted Risk  
  Jennifer Woyach, MD, Blood

Abstracts/Posters

• Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study
  Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• LC-Facseq: A Novel Method for Detecting Rare Resistant Clones in Leukemia
  Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia
  Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (_ 70 Years...
  Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study
  Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL
  Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocy...
  Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (C...
  Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Role of Mutant p53 in the Progression of Chronic Lymphocytic Leukemia
  Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity
  Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy
  Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia
  Jennifer Woyach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (_ 70 Years... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• MRD Testing to Guide Treatment Decisions in CLL 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Response Comes of Age in Chronic Lymphocytic Leukemia 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Acalabrutinib with obinutuzumab (Ob) in treatment-naive (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Three-year follow-up. 
  2019 ASCO Annual Meeting - 6/1/2019
• Mutations in the Ras Pathway in Pre-Treatment Chronic Lymphocytic Leukemia Are Associated with VH1-69: Linking B-Cell Receptor Stereotypy to Downstream Signaling Events 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all